Partial Reprogramming Rejuvenates Aged Cells and Tissues

by September 17, 2025

In a significant advancement in the field of regenerative medicine, recent research has uncovered that partial reprogramming can effectively rejuvenate aged cells and tissues without triggering pluripotency. This study provides insights into the mechanisms of cellular aging and the potential for therapeutic interventions.

Introduction

The aging process is characterized by various molecular and cellular changes, leading to deterioration in tissue function and increased susceptibility to age-related diseases. One notable phenomenon observed with aging is the transition from an epithelial to a mesenchymal state, a process termed mesenchymal drift. This article explores how techniques involving Yamanaka factors can reverse mesenchymal drift and enhance cellular rejuvenation.

Mesenchymal Drift: The Aging Process Unveiled

With age, cells undergo significant epigenetic changes which impede their ability to sustain their original identities. The authors of the study focused on the mesenchymal-epithelial transition (MET), where fibroblasts can revert to a pluripotent state via the application of the Yamanaka factors: Oct4, Sox2, Klf4, and c-Myc. These factors have been shown to ameliorate some of the age-associated cellular transitions.

Key Observations

• The research team noted an increase in pathways linked to epithelial-mesenchymal transition (EMT) across aging tissues.
• They formally defined this phenomenon as mesenchymal drift (MD), describing it as a transition that diminishes the original cellular identity.

Through their investigations, they discovered that mesenchymal drift correlates with several age-related diseases, including:

• Lung diseases
• Liver diseases
• Chronic kidney diseases
• Cardiomyopathies
• Alzheimer’s disease
• Osteoarthritis
• Inflammatory bowel diseases
• Aged skin
• Endothelial cells in calcified atherosclerotic cores

Clinical Implications of Mesenchymal Drift

The findings demonstrated a connection between mesenchymal drift and clinical outcomes, particularly in the context of idiopathic pulmonary fibrosis (IPF). The researchers categorized patients based on gene expression related to mesenchymal drift:

This data indicated a potential role for mesenchymal drift genes as prognostic markers within clinical settings.

Exploring Rejuvenation Mechanisms

Following the establishment of associations between mesenchymal drift and aging, the researchers delved into the causative factors. They scrutinized data across several studies and employed animal models to assess alterations in biological age, particularly through modulation of the regulator of mesenchymal drift, ZEB1.

Effects of Yamanaka Factors

Yamanaka factors have been previously characterized for their ability to reprogram differentiated cells into pluripotent stem cells. However, in their present study, the researchers discovered that even without full pluripotency induction, these factors significantly affected mesenchymal drift.

• Short-term induction of OSKM in aged mice reduced mesenchymal drift gene expression.
• Cellular analysis revealed a "partially reprogrammed" trajectory, indicating early events could dampen mesenchymal drift via MET.

Results Summary

The research concluded that the reductions in mesenchymal drift expression through partial MET provide evidence that rejuvenation can be achieved without necessitating full pluripotency. The results displayed are as follows:

Future Directions and Challenges

Although findings from cell cultures and animal models have shown promising results, further validation in human trials is crucial. The study presents several challenges ahead:

• Optimization of OSKM induction duration specific to cell types.
• Exploration of mesenchymal drift regulators as therapeutic targets in wider aging contexts.

Conclusion

This research adds to a growing body of evidence that partial reprogramming can counteract age-related cellular changes, providing a novel approach to rejuvenation that could impact therapeutic strategies for aging and age-related diseases.

References

[1] Lu, J. Y., et al. (2025). Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming. Cell, S0092-8674(25)00853-0. Advance online publication.

[2] Hernando-Herraez, I., et al. (2019). Ageing affects DNA methylation drift and transcriptional cell-to-cell variability in mouse muscle stem cells. Nature communications, 10(1), 4361.

[3] Izgi, H., et al. (2022). Inter-tissue convergence of gene expression during ageing suggests age-related loss of tissue and cellular identity. eLife, 11, e68048.

[4] Waryah, C., et al. (2023). Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10(22), e2301802.

For further insights and updates on this critical field of research, please visit Lifespan Research Institute.

About the author: Anna graduated from the University of Virginia, where she studied genetics in a tiny worm called C. elegans. She is a freelance science writer specializing in science communication.